Zobrazeno 1 - 10
of 58
pro vyhledávání: ''
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i
Autor:
Jacob George, Philip Newsome, Henning Grønbæk, Manuel Romero-Gómez, Syed-Mohammed Jafri, Lynsey Corless, Joanna Uddén Hemmingsson, Rodolphe Anty, Jude Oben, Vlad Ratziu, Maeva Guillaume
Publikováno v:
Newsome, P N, Buchholtz, K, Cusi, K, Linder, M, Okanoue, T, Ratziu, V, Sanyal, A J, Sejling, A-S, Harrison, S A & NN9931-4296 Investigators 2021, ' A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis ', The New England Journal of Medicine, vol. 384, no. 12, pp. 1113-1124 . https://doi.org/10.1056/NEJMoa2028395
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in p
Autor:
Yuping Dong, Robert Hamlin, Daniel Gaudet, Erik S.G. Stroes, Lesley J. Burgess, Robert Pordy, Nagwa Khilla, Shazia Ali, C. Ebenbichler, Seth J. Baum, Robert S. Rosenson, Vladimir Son
Publikováno v:
New England journal of medicine, 383(24), 2307-2319. Massachussetts Medical Society
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the
Autor:
Jadambaa Tsolmo, Jutmaan Yanjmaa, Murneren Tunsag, Davaasambuu Ganmaa, Saranjav Ariunzaya, Polyna Khudyakov, Tserenkhuu Enkhtsetseg, Erdenebaatar Sumiya, Dorjnamjil Khulan, Garmaa Gantsetseg, Buyanjargal Uyanga, Ben J. Marais, Ankhbat Munkhzaya, Davaasambuu Enkhmaa, Donna Spiegelman, Baigali Delgerekh, Batbileg Bolortuya, James A Seddon, Ochirbat Batbayar, Bazarsaikhan Amarsaikhan, Adrian R. Martineau, Ganbaatar Erdenetuya, Xin Zhou
Publikováno v:
N Engl J Med
BACKGROUND: Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis. Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS: We randomly assigne
Autor:
Kolb, Martin, Raghu, Ganesh, Wells, Athol U, Behr, Jürgen, Richeldi, Luca, Schinzel, Birgit, Quaresma, Manuel, Stowasser, Susanne, INSTAGE Trial Investigators, Benjamin Bondue, Bondue, Benjamin, Martinez, Fernando J
Publikováno v:
The New England journal of medicine, 379 (18
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusio
Autor:
Serpil C. Erzurum, Shamsah Kazani, Kartik Shenoy, Allison Crosby-Thompson, Mario Castro, Katherine N. Cahill, Joshua A. Boyce, Juying Lai, Michael E. Wechsler, Tanya M. Laidlaw, Jennifer Trevor, Elliot Israel, Emily DiMango, Vernon M. Chinchilli, Jing Cui, Denise Garofalo, Nizar N. Jarjour, Howard R. Katz
Publikováno v:
New England Journal of Medicine. 376:1911-1920
Mast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control. Stem cell factor and its
Autor:
Thomas, Ruzicka, Jon M, Hanifin, Masutaka, Furue, Grazyna, Pulka, Izabela, Mlynarczyk, Andreas, Wollenberg, Ryszard, Galus, Takafumi, Etoh, Ryosuke, Mihara, Hiroki, Yoshida, Jonathan, Stewart, Kenji, Kabashima, Agnieszka, Zebrowska
Publikováno v:
New England Journal of Medicine. 376:826-835
Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic d
Autor:
Strosberg, J, El Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, Pl, Kulke, Mh, Jacene, H, Bushnell, D, O'Dorisio, Tm, Baum, Rp, Kulkarni, Hr, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, Jl, Ruszniewski, P, Kwekkeboom, D, Krenning, E, Ansquer, C, Baudin, E, Courbon, F, Giammarile, F, Taieb, D, Scheidhauer, K, Weber, M, Bodei, L, Brianzoni, E, DELLE FAVE, Gianfranco, Chiara Grana, M, Mariani, G, Rindi, G, Severi, S, Azevedo, I, Sundin, A, Al‐nahhas, A, Freemantle, N, Grossman, A, Manoharan, P, Anthony, L, Benson, Ab, Garbus, S, Kulke, M, Kvols, L, Metz, D, Morse, M, Schipper, M, Yao, J.
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of
Autor:
William J, Sandborn, Brian G, Feagan, Douglas C, Wolf, Geert, D'Haens, Severine, Vermeire, Stephen B, Hanauer, Subrata, Ghosh, Heather, Smith, Matthew, Cravets, Paul A, Frohna, Richard, Aranda, Sheila, Gujrathi, Allan, Olson
Publikováno v:
New England journal of medicine, 374(18), 1754-1762. Massachussetts Medical Society
Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal tract. We
Publikováno v:
New England Journal of Medicine. 370:2093-2101
Acetylcysteine has been suggested as a beneficial treatment for idiopathic pulmonary fibrosis, although data from placebo-controlled studies are lacking.In our initial double-blind, placebo-controlled trial, we randomly assigned patients who had idio